Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Luspatercept response predictors in lower-risk myelodysplastic syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

EAEmmanuel AlmanzaThe University of Texas MD Anderson Cancer CenterWJWei‐Ying JenThe University of Texas MD Anderson Cancer CenterKSKoji SasakiThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals response predictors including erythropoiesis and prior hypomethylating agents in lower-risk myelodysplastic syndrome.

Key Points

  • This study aims to identify predictors of response to luspatercept in patients with lower-risk myelodysplastic syndrome.
  • Retrospective analysis of adult patients with LR-MDS treated with luspatercept
  • Patients classified into transfusion burden categories per IWG 2018 criteria
  • Logistic regression was used to identify predictors of response and overall survival analyses were performed using Kaplan-Meier and Cox proportional hazards models.
  • 52 patients (50%) achieved response according to IWG criteria.
  • Higher baseline Hb levels were associated with response (8.7 vs 8.2 g/dL, P = 0.04).
  • Prior hypomethylating agents exposure correlated with lower response rates (25% vs 75% in HMA-naïve).

Cite This Study

Almanza et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d89chttps://doi.org/10.1182/blood-2025-5648
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa2024 · 7 citations
  2. 2The efficacy and safety of luspatercept in patients with low-blasts myelodysplastic neoplasms in real world2025
  3. 3Luspatercept for the treatment of myelodysplastic syndrome: A retrospective cohort study utilizing trinetx2025
  4. 4Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial2025 · 1 citations
  5. 5Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial2025 · 1 citations